Biological and Clinical Database for Pancreatic Adenocarcinoma
BACAP
1 other identifier
observational
1,700
1 country
16
Brief Summary
BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA and RNA from tumors cells. The mission of this prospective project is to make available to the scientific community a clinical biological base from patients with pancreatic adenocarcinoma
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2014
Longer than P75 for all trials
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
June 20, 2016
CompletedFirst Posted
Study publicly available on registry
June 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
ExpectedMarch 21, 2025
March 1, 2025
9.5 years
June 20, 2016
March 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Constitution of a transdisciplinary biobank with collection of biological samples with DNA
The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma
Through the study completion, an average of 11 months
Constitution of a transdisciplinary biobank with collection of biological samples without DNA
The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma
Through the study completion, an average of 11 months
Study Arms (1)
Cohort
Collection of biological samples
Interventions
Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
Eligibility Criteria
Patients with a pancreatic adenocarcinoma proven cytologically or histologically without any treatment
You may qualify if:
- Patient eighteen years old
- Histologically or cytologically confirmed pancreatic adenocarcinoma
- Solid pancreatic mass explored with tomodensitometry or endoscopic ultrasonography fine-needle aspiration
- Informed consent signed
You may not qualify if:
- no informed consent
- pregnancy women
- no histologically or cytologically confirmed pancreatic adenocarcinoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (16)
University Hospital Bordeaux
Bordeaux, 33604, France
Beaujon Hospital
Clichy, 92110, France
University Hospital Lille
Lille, 59037, France
University Hospital of Lille
Lille, 59037, France
Centre Léon Bérard
Lyon, 69008, France
Private Hospital Jean Mermoz
Lyon, 69008, France
Hopital La Timone
Marseille, 13000, France
Hospital Nord
Marseille, 13000, France
Institut Regional du Cancer de Montpellier
Montpellier, 34000, France
University Hospital Montpellier
Montpellier, 34000, France
University Hospital of NICE
Nice, 06202, France
Saint-Louis Hospital
Paris, 75010, France
Clinique du Trocadero
Paris, 75016, France
Pau Hospital
Pau, 64000, France
University Hospital Toulouse
Toulouse, 31059, France
Institut Gustave Roussy
Villejuif, 94805, France
Related Publications (3)
Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel). 2020 Mar 25;12(4):783. doi: 10.3390/cancers12040783.
PMID: 32218346DERIVEDFrere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D; BACAP Consortium. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009. Epub 2019 Dec 14.
PMID: 31843588DERIVEDCanivet C, Gourgou-Bourgade S, Napoleon B, Palazzo L, Flori N, Guibert P, Piessen G, Farges-Bancel D, Seitz JF, Assenat E, Vendrely V, Truant S, Vanbiervliet G, Berthelemy P, Garcia S, Gomez-Brouchet A, Buscail L, Bournet B; BACAP Consortium. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. BMC Cancer. 2018 Oct 16;18(1):986. doi: 10.1186/s12885-018-4906-4.
PMID: 30326968DERIVED
Biospecimen
Whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsie, tissue from tumor and adjacent tissue of pancreas
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Barbara BOURNET, MD; PHD
University Hospital, Toulouse
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2016
First Posted
June 30, 2016
Study Start
May 1, 2014
Primary Completion
November 10, 2023
Study Completion (Estimated)
January 1, 2029
Last Updated
March 21, 2025
Record last verified: 2025-03